Is There a Cure for Cancer? The Better Question Is: Which Cancer, at What Stage, and With Which Treatment?

Picture two people who hear the same sentence on the same afternoon: “The biopsy shows cancer.” One is a young man with a small tumor confined to a testicle. The other is an older woman whose colon cancer has already reached her liver. They now share a word, but almost nothing else — not the biology of their disease, not the treatment plan, not the odds.

That is why “Is there a cure for cancer?” is so hard to answer honestly. The short answer is that there is no single cure, and there is unlikely ever to be one. The longer, more hopeful answer is that many cancers are cured every day. Whether a particular cancer can be cured depends above all on three things: what kind of cancer it is, how far it has spread, and whether there is a treatment that can reach every part of it.

Cancer is not one disease

The National Cancer Institute (NCI) describes cancer as a disease in which some of the body’s cells grow uncontrollably and spread to other parts of the body — and it counts more than 100 types. Underneath, cancer is a genetic disease: it is driven by changes to genes that control how cells grow and divide.

Those changes differ from tumor to tumor, and they matter. A leukemia (a cancer of blood-forming cells) and a melanoma (a skin cancer) behave like different illnesses, respond to different drugs and follow different timelines. Even two lung cancers can differ so much at the molecular level that one responds to a pill aimed at a specific mutation while the other does not. Much of modern oncology is the work of telling these diseases apart — the subject of our guide to the new cancer toolkit.

Cure, remission, “no evidence of disease”: three different claims

Doctors tend to use the word “cure” sparingly, and for good reason. NCI’s guide to prognosis draws the distinctions clearly:

• Remission means the signs and symptoms of cancer are reduced. It can be partial or complete; in a complete remission, all signs and symptoms have disappeared.
• No evidence of disease (NED) is the phrase clinicians often use when tests and scans cannot find any cancer. It is an honest statement about the limits of detection: a scan cannot see a handful of stray cells.
• Cure, in NCI’s words, means there are no traces of the cancer after treatment and the cancer will never come back.

That last clause — never come back — can only be confirmed in hindsight. So in practice, NCI notes, if someone remains in complete remission for five years or more, some doctors may say they are cured. For some cancers the risk of return fades quickly; others can recur many years later, which is why follow-up visits often continue long after treatment ends.

Plain English: “Remission” and “no evidence of disease” describe what doctors can see now. “Cure” is a claim about the future — which is why it is made cautiously, and often only after years without a return.

Stage: the map that changes everything

If type is the first question, stage is the second. Staging is the process of working out how much cancer is in the body and whether it has spread. The most widely used system, called TNM, scores three things: the size and extent of the main Tumor, whether cancer is in nearby lymph Nodes, and whether it has Metastasized — spread to distant parts of the body.

Those scores are usually summarized as a stage. Stage 0 means abnormal cells are present but have not spread into nearby tissue (sometimes called carcinoma in situ). Stages I to III mean cancer is present, with higher numbers indicating a larger tumor or more spread into nearby tissue. Stage IV means the cancer has reached distant parts of the body.

Look at what that does to outcomes. In U.S. data from NCI’s SEER program for people diagnosed with colorectal cancer between 2016 and 2022, five-year relative survival — survival compared with people of the same age who do not have cancer — was about 91% when the cancer was localized, about 75% when it had reached regional lymph nodes, and about 17% when it had spread to distant organs. Same organ, same broad diagnosis, profoundly different prospects.

Two caveats matter. These figures describe large groups, not any individual. And because they look back at people diagnosed years ago, they may not fully reflect newer treatments.

Why spread is the dividing line

The reason stage matters so much is partly mechanical. NCI notes that surgery works best for solid tumors that are contained in one area. If a cancer is still in one place, a surgeon can often remove it entirely, sometimes with radiation or drugs added to mop up cells that might have escaped. That is how many early-stage solid cancers are cured.

Once cancer has seeded itself in distant organs, treatment has to travel everywhere cancer cells might be hiding — which means systemic therapies (drugs that circulate through the whole body) such as chemotherapy, hormone therapy, targeted drugs or immunotherapy. Some cancers are exquisitely sensitive to these treatments. Many are not, or become resistant over time.

A cure is not a single discovery waiting in a vault. It is a match between a specific disease, caught at a specific moment, and a treatment able to reach all of it.

Cancers that are often curable today

Some of medicine’s quietest triumphs are cancers that were once frequently fatal and are now usually cured. NCI’s expert-reviewed treatment summaries (known as PDQ) are unusually direct about them:

• Testicular cancer. NCI calls it a highly treatable, usually curable cancer. For low-stage disease, the cure rate approaches 100%, and even patients whose cancer has spread widely at diagnosis may have curable disease.
• Hodgkin lymphoma. A cancer of the lymphatic system. According to NCI, up to 90% of newly diagnosed patients can be cured with combination chemotherapy and/or radiation therapy.
• Childhood acute lymphoblastic leukemia (ALL). The most common childhood cancer. Between 1975 and 2020, five-year survival for children younger than 15 rose from 60% to approximately 90%, according to NCI.
• Many early-stage solid tumors. When cancers of organs such as the colon or breast are found while still localized, treatment aimed at cure — often surgery, sometimes with added therapy — is frequently successful, as the stage-by-stage survival figures above suggest.

What these successes have in common is instructive. They reflect decades of carefully designed clinical trials that refined drug combinations and doses, biology that happens to be vulnerable to the treatments we have, and — for solid tumors — catching disease before it spreads.

Cure can come with a bill

Survival is not the end of the story. NCI’s summary on Hodgkin lymphoma reports that, 15 to 20 years after therapy, the combined death toll from second cancers, heart disease and lung scarring among survivors exceeds the toll from the lymphoma itself. Survivors of childhood ALL can face “late effects” such as learning and memory problems or second cancers. That is why much current research on highly curable cancers aims to keep cure rates high while giving less treatment.

When control, not cure, is the goal

For many advanced cancers, the honest goal is not cure but control: shrinking tumors, slowing growth, easing symptoms and extending good-quality life. That is not a consolation prize. Some cancers that were once rapidly fatal can now be managed for long periods with daily pills or periodic infusions, and a minority of people with advanced disease treated with newer immunotherapies experience long-lasting responses. For others, progress has been painfully slow.

Treatment teams often talk about goals explicitly — cure, control or comfort — because the right choices, and acceptable side effects, depend on which one is realistic. Those conversations belong between a patient and their care team; general articles like this one can only explain the vocabulary.

Why “cure” headlines keep misleading

Every year brings headlines about a compound that “destroys cancer cells.” Most describe experiments in cell cultures or mice — the preclinical stage. Plenty of substances kill cancer cells in a dish, and most drug candidates that enter human trials never reach approval. Our explainer on how to read a biotech breakthrough walks through the warning signs, and our interactive Breakthrough Reality Check lets you practise.

A more useful set of questions — the ones specialists themselves ask — looks like this:

1. What exact type and subtype of cancer is this?
2. What stage is it, and has it spread?
3. Does the tumor carry markers that predict response to particular drugs?
4. Is the realistic goal of treatment cure, long-term control or comfort?
5. What are the short- and long-term costs of treatment?
6. Was the evidence gathered in cells, animals or people — and in how many?

The better question

Asking “Is there a cure for cancer?” is a bit like asking whether there is a cure for infection. There isn’t one — but there are cures for many infections, treatments that control others, and some we still struggle against. Cancer is similar. The progress is real and, for some diseases, spectacular. It is also uneven, hard-won and specific.

So the better question is the one in our headline: which cancer, at what stage, and with which treatment? Ask it that way, and the answer is often more hopeful — and always more honest — than any headline promising a universal cure.